Two technologies. One company holds both.
A commercialized precision hyperthermia device and a next-generation heat-triggered medicine, advanced under unified control. No competitor pairs the two, and precision heat enhances every modality it touches.
A device and a medicine, under one roof.
One control layer. Every modality.
Avenor is built to fit everywhere heat can improve cancer treatment, not to sell a single drug. Precision heat is an enabling technology that makes today's and tomorrow's therapies more effective, more selective, and less toxic. Beyond enhancing existing treatments, it forms the foundation of a proprietary platform for heat-activated medicines, creating opportunities across a broad range of oncology indications.
A scalable, defensible platform with applications across a broad range of solid tumors.
The missing control layer in oncology
Cancer treatment, radiotherapy, chemotherapy, and the therapies still to come, is limited not by a lack of potent tools, but by an inability to precisely control where and when they exert their effects.
Tumor biology fights back, reducing treatment effectiveness while forcing the higher doses that drive toxicity.
Avenor introduces a new biological control mechanism: precision heat.
One trigger. Multiple applications.
The ALBA platform delivers focused, controllable, mild hyperthermia straight to the tumor, a physical trigger a clinician directs in real time. Above a precise threshold, heat stops being a side effect and becomes a therapeutic lever, one capable of carrying a range of therapeutic payloads. THE001 is our lead application: it sensitizes, perfuses, activates, and releases whatever therapy it is paired with.
Loco-regional hyperthermia, applied with precision.
ALBA heats only the target region into a narrow therapeutic window, roughly 40 to 43°C, and holds it there while sparing surrounding healthy tissue. The clinician controls where the heat lands, when it starts, and exactly how long it stays at threshold. ALBA hyperthermia platform offers RT-like precision, controllable, fast and reproducible heating profiles, seamlessly integrated into radiotherapy workflows.
Sensitize
Mild hyperthermia inhibits DNA repair and preferentially damages hypoxic tumor cells, potentiating the anti-tumor activity of radiation and chemotherapy without raising systemic dose.
Perfuse
Heat reduces interstitial fluid pressure and improves tumor perfusion and oxygenation, driving deeper, more uniform drug penetration into the tumor core.
Activate
Hyperthermia triggers immunogenic cell death and DAMP release, amplifying anti-tumor immunity and the efficacy of immunotherapy.
Release
Thermosensitive carriers stay sealed at body temperature and open only inside the heated zone, delivering up to 15-fold higher local drug concentration.
Sealed
A proprietary phospholipid shell locks the drug inside at body temperature, fully inactive.
In transit
Intact liposomes circulate in the blood stream, sparing healthy tissue.
Heated
The ALBA device warms the tumor to the precise release threshold.
Released
The shell opens quickly, flooding the tumor with a concentrated dose, up to 15× local levels.
Proprietary, validated, and built to extend.
The Release mechanism runs on a proprietary thermosensitive-liposome technology with completed preclinical work and a completed Phase I, an unequivocal proof of principle for heat-triggered delivery. The same carrier is programmable: swap the payload and the platform reaches new indications and new drug classes, generating a new treatment pillar in oncology and beyond.
Preclinical and Phase I complete · exclusive worldwide rights · Orphan Drug Designation, US & EU